291 related articles for article (PubMed ID: 34776417)
1. Neurofilament Levels in CSF and Serum in an Adult SMA Cohort Treated with Nusinersen.
Rich KA; Fox A; Yalvac M; Heintzman S; Tellez M; Bartlett A; Severyn S; Linsenmayer M; Kelly K; Reynolds J; Sterling GB; Weaver T; Rajneesh K; Pino MG; Arnold WD; Elsheikh B; Kolb SJ
J Neuromuscul Dis; 2022; 9(1):111-119. PubMed ID: 34776417
[TBL] [Abstract][Full Text] [Related]
2. Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersen.
Wurster CD; Steinacker P; Günther R; Koch JC; Lingor P; Uzelac Z; Witzel S; Wollinsky K; Winter B; Osmanovic A; Schreiber-Katz O; Al Shweiki R; Ludolph AC; Petri S; Hermann A; Otto M;
J Neurol; 2020 Jan; 267(1):36-44. PubMed ID: 31552549
[TBL] [Abstract][Full Text] [Related]
3. Comparison of neurofilament light and heavy chain in spinal muscular atrophy and amyotrophic lateral sclerosis: A pilot study.
Li JY; Dai Y; Sun XH; Ren HT; Shen DC; Yang XZ; Liu MS; Cui LY
Brain Behav; 2023 May; 13(5):e2997. PubMed ID: 37070132
[TBL] [Abstract][Full Text] [Related]
4. Biochemical and clinical biomarkers in adult SMA 3-4 patients treated with nusinersen for 22 months.
De Wel B; De Schaepdryver M; Poesen K; Claeys KG
Ann Clin Transl Neurol; 2022 Aug; 9(8):1241-1251. PubMed ID: 35833245
[TBL] [Abstract][Full Text] [Related]
5. Neurofilament Heavy Chain and Tau Protein Are Not Elevated in Cerebrospinal Fluid of Adult Patients with Spinal Muscular Atrophy during Loading with Nusinersen.
Totzeck A; Stolte B; Kizina K; Bolz S; Schlag M; Thimm A; Kleinschnitz C; Hagenacker T
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31671515
[TBL] [Abstract][Full Text] [Related]
6. Neurofilament changes in serum and cerebrospinal fluid after acute ischemic stroke.
Pujol-Calderón F; Portelius E; Zetterberg H; Blennow K; Rosengren LE; Höglund K
Neurosci Lett; 2019 Apr; 698():58-63. PubMed ID: 30599262
[TBL] [Abstract][Full Text] [Related]
7. Comparison of CSF and plasma NfL and pNfH for Alzheimer's disease diagnosis: a memory clinic study.
Vrillon A; Ashton NJ; Karikari TK; Götze K; Cognat E; Dumurgier J; Lilamand M; Zetterberg H; Blennow K; Paquet C
J Neurol; 2024 Mar; 271(3):1297-1310. PubMed ID: 37950758
[TBL] [Abstract][Full Text] [Related]
8. Nusinersen treatment and cerebrospinal fluid neurofilaments: An explorative study on Spinal Muscular Atrophy type 3 patients.
Faravelli I; Meneri M; Saccomanno D; Velardo D; Abati E; Gagliardi D; Parente V; Petrozzi L; Ronchi D; Stocchetti N; Calderini E; D'Angelo G; Chidini G; Prandi E; Ricci G; Siciliano G; Bresolin N; Comi GP; Corti S; Magri F; Govoni A
J Cell Mol Med; 2020 Mar; 24(5):3034-3039. PubMed ID: 32032473
[TBL] [Abstract][Full Text] [Related]
9. Neurofilaments in Sporadic and Familial Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis.
Shahim P; Norato G; Sinaii N; Zetterberg H; Blennow K; Chan L; Grunseich C
Genes (Basel); 2024 Apr; 15(4):. PubMed ID: 38674431
[TBL] [Abstract][Full Text] [Related]
10. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study.
Walter MC; Wenninger S; Thiele S; Stauber J; Hiebeler M; Greckl E; Stahl K; Pechmann A; Lochmüller H; Kirschner J; Schoser B
J Neuromuscul Dis; 2019; 6(4):453-465. PubMed ID: 31594243
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal Fluid and Clinical Profiles in Adult Type 2-3 Spinal Muscular Atrophy Patients Treated with Nusinersen: An 18-Month Single-Centre Experience.
Milella G; Introna A; D'Errico E; Fraddosio A; Scaglione G; Morea A; Ucci M; Ruggieri M; Mastrapasqua M; Megna M; Puntillo F; Simone IL
Clin Drug Investig; 2021 Sep; 41(9):775-784. PubMed ID: 34389971
[TBL] [Abstract][Full Text] [Related]
12. Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease.
Poesen K; De Schaepdryver M; Stubendorff B; Gille B; Muckova P; Wendler S; Prell T; Ringer TM; Rhode H; Stevens O; Claeys KG; Couwelier G; D'Hondt A; Lamaire N; Tilkin P; Van Reijen D; Gourmaud S; Fedtke N; Heiling B; Rumpel M; Rödiger A; Gunkel A; Witte OW; Paquet C; Vandenberghe R; Grosskreutz J; Van Damme P
Neurology; 2017 Jun; 88(24):2302-2309. PubMed ID: 28500227
[TBL] [Abstract][Full Text] [Related]
13. Neurochemical markers in CSF of adolescent and adult SMA patients undergoing nusinersen treatment.
Wurster CD; Günther R; Steinacker P; Dreyhaupt J; Wollinsky K; Uzelac Z; Witzel S; Kocak T; Winter B; Koch JC; Lingor P; Petri S; Ludolph AC; Hermann A; Otto M
Ther Adv Neurol Disord; 2019; 12():1756286419846058. PubMed ID: 31205491
[TBL] [Abstract][Full Text] [Related]
14. Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS.
Benatar M; Zhang L; Wang L; Granit V; Statland J; Barohn R; Swenson A; Ravits J; Jackson C; Burns TM; Trivedi J; Pioro EP; Caress J; Katz J; McCauley JL; Rademakers R; Malaspina A; Ostrow LW; Wuu J;
Neurology; 2020 Jul; 95(1):e59-e69. PubMed ID: 32385188
[TBL] [Abstract][Full Text] [Related]
15. Intrathecal nusinersen treatment after ventriculo-peritoneal shunt placement: A case report focusing on the neurofilament light chain in cerebrospinal fluid.
Tozawa T; Kasai T; Tatebe H; Shiomi K; Nishio H; Tokuda T; Chiyonobu T
Brain Dev; 2020 Mar; 42(3):311-314. PubMed ID: 31889567
[TBL] [Abstract][Full Text] [Related]
16. NFL is a marker of treatment response in children with SMA treated with nusinersen.
Olsson B; Alberg L; Cullen NC; Michael E; Wahlgren L; Kroksmark AK; Rostasy K; Blennow K; Zetterberg H; Tulinius M
J Neurol; 2019 Sep; 266(9):2129-2136. PubMed ID: 31123861
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the neurofilament light chain as a biomarker in children with spinal muscular atrophy treated with nusinersen.
Seo G; Kim S; Byun JC; Kwon S; Lee YJ
Brain Dev; 2023 Nov; 45(10):554-563. PubMed ID: 37541812
[TBL] [Abstract][Full Text] [Related]
18. Serum neurofilament light chain in pediatric spinal muscular atrophy patients and healthy children.
Nitz E; Smitka M; Schallner J; Akgün K; Ziemssen T; von der Hagen M; Tüngler V
Ann Clin Transl Neurol; 2021 Oct; 8(10):2013-2024. PubMed ID: 34482646
[TBL] [Abstract][Full Text] [Related]
19. Correlations between serum and CSF pNfH levels in ALS, FTD and controls: a comparison of three analytical approaches.
Wilke C; Pujol-Calderón F; Barro C; Stransky E; Blennow K; Michalak Z; Deuschle C; Jeromin A; Zetterberg H; Schüle R; Höglund K; Kuhle J; Synofzik M
Clin Chem Lab Med; 2019 Sep; 57(10):1556-1564. PubMed ID: 31251725
[TBL] [Abstract][Full Text] [Related]
20. Total tau in cerebrospinal fluid detects treatment responders among spinal muscular atrophy types 1-3 patients treated with nusinersen.
Šimić G; Vukić V; Babić M; Banović M; Berečić I; Španić E; Zubčić K; Golubić AT; Barišić Kutija M; Merkler Šorgić A; Vogrinc Ž; Lehman I; Hof PR; Sertić J; Barišić N
CNS Neurosci Ther; 2024 Mar; 30(3):e14051. PubMed ID: 36513962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
